ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 89 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $80,551 | -38.2% | 7,035 | -44.5% | 0.00% | – |
| Q2 2023 | $130,361 | +284.5% | 12,681 | +188.7% | 0.00% | – |
| Q1 2023 | $33,906 | +3290.6% | 4,392 | +3358.3% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 127 | -56.2% | 0.00% | – |
| Q2 2022 | $2,000 | -96.1% | 290 | -94.9% | 0.00% | – |
| Q1 2022 | $51,000 | -60.8% | 5,703 | -39.6% | 0.00% | – |
| Q4 2021 | $130,000 | -77.8% | 9,438 | -82.8% | 0.00% | – |
| Q3 2021 | $585,000 | +19400.0% | 54,878 | +18192.7% | 0.00% | – |
| Q2 2021 | $3,000 | -25.0% | 300 | -18.0% | 0.00% | – |
| Q1 2021 | $4,000 | +300.0% | 366 | +446.3% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 67 | +6.3% | 0.00% | – |
| Q3 2020 | $1,000 | – | 63 | +142.3% | 0.00% | – |
| Q2 2020 | $0 | – | 26 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 26 | -93.5% | 0.00% | – |
| Q2 2019 | $2,000 | -33.3% | 400 | 0.0% | 0.00% | – |
| Q1 2019 | $3,000 | -96.6% | 400 | -96.4% | 0.00% | – |
| Q1 2018 | $88,000 | -25.4% | 10,993 | +4.0% | 0.00% | – |
| Q4 2017 | $118,000 | – | 10,569 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 2,571,450 | $23,143,000 | 2.13% |
| Omega Fund Management, LLC | 1,284,900 | $11,564,000 | 1.31% |
| Avidity Partners Management LP | 1,495,000 | $13,455,000 | 0.36% |
| Samsara BioCapital, LLC | 275,169 | $2,477,000 | 0.31% |
| Orbimed Advisors | 3,070,955 | $27,639,000 | 0.28% |
| Ikarian Capital, LLC | 300,454 | $2,704,000 | 0.22% |
| TIGER MANAGEMENT L.L.C. | 137,728 | $1,240,000 | 0.22% |
| DAFNA Capital Management LLC | 113,302 | $1,020,000 | 0.21% |
| EcoR1 Capital, LLC | 522,635 | $4,704,000 | 0.18% |
| Artal Group S.A. | 593,030 | $5,337,000 | 0.11% |